Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trial

References

• Antonijevic, Z., Bolognese, J., Burman, C. F., Chuang-Stein, C., Jennison, C., Kimber, M., Marchenko, O., Patel, N., Pinheiro, J. (2013). A progress report from the DIA adaptive program work stream. Biopharmaceutical Report 20:3–9.
   Google Scholar
• Ashby, D., Tan, S. B. (2005). Where’s the utility in Bayesian data-monitoring of clinical trials? Clinical Trials 2:197–208
   Web of Science ®Google Scholar
• Barker, A. D., Sigman, C. C., Kelloff, G. J., Hylton, N. M., Berry, D. A., Esserman, L. J. (2009). I‐ SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology & Therapeutics 86:97–100
   PubMed Web of Science ®Google Scholar
• Berry, S. M., Spinelli, W., Littman, G. S., Liang, J. Z., Fardipour, P., Berry, D. A., Lewis, R. J., Krams, M. (2010). A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug. Clinical Trials 7:121–135
   PubMed Web of Science ®Google Scholar
• Bjornsson, T. D., Wagner, J. A., Donahue, S. R., Harper, D., Karim, A., Khouri, M. S., Murphy, W. R., Roman, K., Schneck, D., Sonnichsen, D. S., Stalker, D. J., Wise, S. D., Dombey, S., Loew, C. (2003). A review and assessment of potential sources of ethnic differences in drug responsiveness. The Journal of Clinical Pharmacology 43: 943–967
   PubMed Web of Science ®Google Scholar
• Chen, J. J., Novick, M. R. (1984). Bayesian analysis for binomial models with generalized beta prior distributions. Journal of Educational Statistics 9:163–175
   Google Scholar
• Fatkenheuer, G., Pozniak, A. L., Johnson, M. A., Plettenberg, A., Staszewski, S., Hoepelman, A. I., Saag, S. M., Goebel, D. F., Rockstroh, K. J., Dezube, J. B., Jenkins, M. T., Medhurst, C., Sullvian, F. J., Ridgway, C., Abel, S., James, T. I., Youle, M., Ryst, E. (2005). Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nature Medicine 11:1170–1172
   PubMed Web of Science ®Google Scholar
• Gilks, W. R., Richardson, S., Spiegelhalter, D. J. (1996). Markov Chain Monte Carlo in Practice. London, England: Chapman & Hall.
   Google Scholar
• Graf, A. C., Posch, M., Koenig, F. (2015). Adaptive designs for subpopulation analysis optimizing utility functions. Biometrical Journal 57: 76–89
   PubMed Web of Science ®Google Scholar
• Huang, S. M., Temple, R. (2008). Is this the drug or dose for you?: Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clinical Pharmacology & Therapeutics 84:287–294
   Web of Science ®Google Scholar
• Jiang, F., Jack Lee, J., Müller, P. (2013). A Bayesian decision-theoretic sequential response-adaptive randomization design. Statistics in Medicine 32:1975–1994
   PubMed Web of Science ®Google Scholar
• Kimani, P. K., Glimm, E., Maurer, W., Hutton, J. L., Stallard, N. (2012). Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods. Statistics in Medicine 31:2068–2085
   PubMed Web of Science ®Google Scholar
• Lee, J., Thall, P. F., Ji, Y., Müller, P. (2015). Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity. Journal of the American Statistical Association 110:711–722
   PubMed Web of Science ®Google Scholar
• Lisovskaja, V., Burman, C. F. (2013). On the choice of doses for phase III clinical trials. Statistics in Medicine 32:1661–1676
   PubMed Web of Science ®Google Scholar
• Marchenko, O., Miller, J., Parke, T., Perevozskaya, I., Qian, J., Wang, Y. (2013). Improving oncology clinical programs by use of innovative designs and comparing them via simulations. Therapeutic Innovation & Regulatory Science 47:602–612
   PubMed Web of Science ®Google Scholar
• Morita, S., Sakamoto, J. (2006). Application of an adaptive design to a randomized phase II selection trial in gastric cancer: A report of the study design. Pharmaceutical Statistics 5: 109–118
   PubMed Web of Science ®Google Scholar
• Morita, S., Müller, P. (2017). Bayesian population finding with biomarkers in a randomized clinical trial. Biometrics 73:1355–1365
   PubMed Web of Science ®Google Scholar
• Müller, P., Berry, D. A., Grieve, A. P., Krams, M. (2006). A Bayesian decision theoretic dose finding trial. Decision Analysis 3:197–207
   Google Scholar
• O’Hagan, A., Stevens, J. W., Campbell, M. J. (2005). Assurance in clinical trial design. Pharmaceutical Statistics 4: 187–201
   Web of Science ®Google Scholar
• Padmanabhan, S. K., Berry, S., Dragalin, V., Krams, M. (2012). A Bayesian dose-finding design adapting to efficacy and tolerability response. Journal of Biopharmaceutical Statistics 22:276–293
   PubMed Web of Science ®Google Scholar
• Patel, N., Bolognese, J., Chuang-Stein, C., Hewitt, D., Gammaitoni, A., Pinheiro, J. (2012). Designing phase 2 trials based on program-level considerations: A case study for neuropathic pain. Drug Information Journal 46:439–454
   Google Scholar
• Phamaceuticals and Medical Devices Agency. (2008). Review Reports (Maraviroc) http: //www.pfizer.co.jp/pfizer/development/clinical_development/190309524003000398399024003000476821524003000new_medicine_info/documents/shinsa/shinsa_h20_12_celsentrl_00.pdf. (in Japanese).
   Google Scholar
• Phamaceuticals and Medical Devices Agency. (2015). Review Reports (Edaravone) http://www.pmda.go.jp/drugs/2015/P20150625003/400315000_21300AMZ00377_A100_1.pdf. (in Japanese).
   Google Scholar
• Saag, M., Goodrich, J., Fätkenheuer, G., Clotet, B., Clumeck, N., Sullivan, J., Westby, M., Ryst, E., Mayer, H. (2009). A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. Journal of Infectious Diseases 199:1638–1647
   PubMed Web of Science ®Google Scholar
• Simon, N., Simon, R. (2017). Using Bayesian modeling in frequentist adaptive enrichment designs. Biostatistics 00:1–15
   Google Scholar
• Smith, M. K., Jones, I., Morris, M. F., Grieve, A. P., Tan, K. (2006). Implementation of a Bayesian adaptive design in a proof of concept study. Pharmaceutical Statistics 5:39-50
   PubMed Web of Science ®Google Scholar
• Tan, S. B., Smith, A. F. M. (1998). Exploratory thoughts on clinical trials with utilities. Statistics in Medicine 17: 2771–2791
   PubMed Web of Science ®Google Scholar
• Thall, P. F., Sung, H. G. (1998). Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Statistics in Medicine 17:1563–1580
   Web of Science ®Google Scholar
• Thall, P. F., Nguyen, H. Q. (2012). Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes. Journal of Biopharmaceutical Statistics 22:785–801
   PubMed Web of Science ®Google Scholar
• Harrison, J., West, M. (1999). Bayesian Forecasting and Dynamic Models. New York: Springer.
   Google Scholar
• Woodcock, J., Woosley, R. (2008). The FDA critical path initiative and its influence on new drug development. Annual Review of Medicine 59:1–12
   PubMed Web of Science ®Google Scholar
• Zang, Y., Lee, J. J. (2014). Adaptive clinical trial designs in oncology. Chinese Clinical Oncology 3:1–20
   Google Scholar
• Zhang, Y., Trippa, L., Parmigiani, G. (2016). Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers. Biometrics 72:414–421
   Web of Science ®Google Scholar
• Zhou, X., Liu, S., Kim, E. S., Herbst, R. S., Lee, J. J. (2008). Bayesian adaptive design for targeted therapy development in lung cancer―a step toward personalized medicine. Clinical Trials 5:181–193
   PubMed Web of Science ®Google Scholar